Background: The electrophysiologic and antifibrillatory properties of tedisamil (KC-8857;3,7-di-(cyclopropylmethyl)-9,9-tetramethylene-3,7-diazabicyclo[3.3.1]-nonane dihydrochloride) were studied in a conscious canine model of sudden cardiac death.
Methods and Results: Three to five days after surgically induced myocardial infarction (2-hour occlusion of the left anterior descending coronary artery), animals were subjected to programmed electrical stimulation to identify those at risk for ischemia-induced ventricular fibrillation. Sixty minutes after tedisamil (10 mg/kg, administered orally) PES was repeated. Tedisamil increased the ventricular effective refractory period from 106 ± 6 to 134 ± 7 ms (P < .05) compared to placebo treatment. which did not alter the ERP (123 ± 6 to 116 ± 5 ms). Tedisamil prolonged the QTc interval. from a predrug value of 308 ± 14 to 327 ± 14 ms, postdrug. The extent of the surgically induced anterior wall myocardial infarct did not differ between groups. tedisamil, 29 ± 2%, and placebo, 28 ± 2% of the left ventricle.
Conclusions: Tedisamil conferred protection against ischemia induced ventricular fibrillation; 7 of 10 tedisamil-treated dogs survived. compared to 4 of 14 surviving in the vehicle treated group (P < .05). Although we observed instances of vomiting and/or diarrhea in several dogs after a single oral administration of tedisamil. the data indicate that oral administration of tedisamil provides protection from ischemia-induced ventricular fibrillation in the postinfarcted conscious canine. The mechanism by which tedisamil achieves its antifibrillatory effect may be related to its ability to prolong the ERP of the ventricular myocardium without altering ventricular conduction velocity.
1. Lazdunski M. Potassium channels: structure-function relationships, diversity. and pharmacology. Cardiovasc Drugs Ther6:313, 1992
2.
2. Escande D, Henry P. Potassium channels as phmacological targets in cardiovascular medicine. Eur Heart J14: Suppl B2, 1993
3.
3. Carmeliet E. Potassium channels in cardiac cells. Cardiovasc Drug Ther6:305, 1992
4.
4. Lynch JJ, Coskey LA, Montgomery DG, Lucchesi BR. Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. Am Heart J109:949, 1985
5.
5. Black SC, Chi L, Mu DX, Lucchesi BR. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. J Pharm Exp Ther258:416, 1991
6.
6. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol22:810, 1993
7.
7. Singh BN. Control of cardiac arrhythmias by prolonging repolarization: historical development of the concept and emerging perspectives. In Singh BN, Wellens HJJ, Hiraoka M (eds). Electropharmacological Control of Cardiac Arrhythmias: To Delay Conduction or to Prolong Refractoriness?Futura Publishing, Mount Kisco, NY, pp 427–440, 1994
8.
8. Dukes ID, Morad M. Tedisamil inactivates transient outward K+ current in rat ventricular myocytes. Am J Physiol257:H1746, 1989
9.
9. Dukes ID, Cleemann L, Morad M. Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. J Pharm Exp Ther254:560, 1990
10.
10. McLarnon JG, Sawyer D, Michikawa M, Kim SU. Tedisamil blocks a calcium-dependent potassium channel in cultured motoneurons. Neurosci Lett144:185, 1992
11.
11. Chi L, Park JL, Friedrichs GS, Banglawala YA, Perez MA, Tanhehco EJ, Lucchesi BR.Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br J Pharmacol117:1261, 1996
12.
12. Tsuchihashi K, Curtis MJ. Influence of tedisamil on the initiation and maintenance of ventricular fibrillation: chemical defibrillation by Ito blockade. J Cardiovasc Pharmacol18:445, 1991
13.
13. Adaikan G, Beatch GN, Lee TL, Ratnam SS, Walker MJA.Antiarrhythmic actions of tedisamil: studies in rats and primates. Cardiovasc Drugs Ther6:345, 1992
14.
14. Bril A, Landais L, Gout B. Actions and interactions of E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo. Cardiovasc Drugs Ther7:233, 1993
15.
15. Patterson E, Holland K, Eller BT, Lucchesi BR.Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction: a conscious canine model of suddcn coronary death. Am J Cardiol50:1414, 1982
16.
16. Woosley RL. Antiarrhythmic drugs. Annu Rev Pharm Toxicol31:427, 1991
17.
17. Ellingboe JW, Spinelli W, Winkey MW, et al. Class III antiarrhythmic activity of novel substituted 4-[(methylsul-fonyl) amino] benzamides and sulfonamides. J Med Chem35:705, 1992
18.
18. Takanaka C, Sarma JSM, Singh BN. Electrophysiological effects of ambasilide (LV 47110), a novel class III antiarrhythmic agent, on properties of isolated rabbit and canine cardiac muscle. J Cardiovasc Pharmacol19:290, 1992
19.
19. Lynch JJ, DiCarla LA, Montgomery DG, Lucchesi BR. Electrophysiologic effects of bepridil in normal and infarcted canine myocardium. J Cardiovasc Pharmacol8:957, 1986
20.
20. Friedrichs GS, Chi L, Gralinski MR, et al. MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death. J Cardiovasc Pharmacol25:314, 1995
21.
21. Richards DAB, Byth K, Ross DL, Uther JB. What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction?Circulation83:756, 1991
22.
22. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators.Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med321:406, 1989
23.
23. The Cardiac Arrhythmia Suppression Trial II Investigators.Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med327:227, 1992
24.
24. Wallace AA, Stupienski RF, Baskin EP, et al. Cardiac electrophysiologic and antiarrhythmic actions of tedisamil. J Pharm Exp Ther273:168, 1995
25.
25. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsade de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol16:276, 1990
26.
26. Myergurg RJ, Kessler KM, Castellanos A. Sudden cardiac death: sturcture, function and time-dependence of risk. Circulation85:12, 1992
27.
27. Lynch JJ, DiCarlo LA, Montgomery DG, Lucchesi BR. Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. Pharmacology35:181, 1987
28.
28. Kou WH, Nelson SD, Lynch JJ, Montgomery DG, DiCarlo L, Lucchesi BR. Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the carly postmyocardial infarction period: evaluation in a conscious canine model of sudden death. J Am Coll Cardiol9:359, 1987
29.
29. Beatch GN, MacLeod BA, Abraham S, Walker MJA. The in vivo electrophysiological actions of the new potassium channel blockers, tedisamil and UK 68,798. Proc West Pharmacol Soc33:5, 1990
30.
30. Pfründer D, Kreye VAW. Tedisamil inhibits the delayed rectifier K+ current in single smooth muscle cells of the guinea-pig portal vein. Pflügers Arch421:22, 1992
31.
31. Pfründer D, Kreye VAW. Tedisamil blocks single large-conductance Ca+2-activated K+ channels in membrane patches from smooth muscle cells of the guinea-pig portal vein. Pflügers Arch418:308, 1991
